News
Vodafone partners with Wales women’s rugby team to track periods and performance
Wales Women will be using the tracking app during the Six Nations Championship
Vodafone has teamed up with the Wales women’s Rugby team to track and research how the menstrual cycle impacts performance, wellbeing and recovery.
Vodafone, who is a founding principal partner of Wales Women’s and Girls rugby, has added menstrual cycle tracking to their PLAYER.Connect platform, which aggregates data from athletes’ wearable devices.
The platform gathers data on players’ performance, menstrual cycle phases and mental and physical wellbeing, by combining data from wearable devices such as GPS trackers in real time.
This is in addition to input from the players themselves, via daily ‘morning monitoring’ – a series of questions answered by the players on arrival at training.
The Wales Women’s team is the first female team to try out the tracking feature.
“Despite 93 per cent of female rugby players reporting menstrual cycle-related symptoms and 67 per cent believing these severely impair their performances, there is limited guidance available on how players can best manage this,” says Alex Skelton, PLAYER.Connect head of performance.
“Being able to directly link each athlete’s menstrual cycle stage to their performance data provides a massive advantage in how we can begin to tackle this issue, by allowing coaches and analysts to move away from ‘catch-all’ solutions and provide genuine tailoring of diet, training and preparation for each individual player.
“Combined with a long-term research study using our PLAYER.Connect data, this will allow us to make huge strides in how we help female athletes of all levels better understand and manage their cycle.”

Rugby player Cerys Hale
Joanna Perkins, Welsh Rugby Union’s national women’s physiotherapist, says the platform is already having a significant impact on the players’ training and preparation.
“PLAYER.Connect gives us information in real time, and is far more user friendly,” she explains.
“That means we can quickly implement strategies, inform change, avoid injuries, and help players reach their peak preparation ahead of each fixture.”
Wales Women prop, Cerys Hale, says the PLAYER.Connect technology has improved her performance this season.
“It’s given me a greater awareness of things I need to do away from the field, so for example I can monitor any soreness, be more aware of how I’m recovering and then look at what I can do before training to help manage injury prevention.
“This includes tips on how I can change my nutrition during each of the phases of my cycle, how I can reduce my symptoms, and it’s just given me more confidence that I’m putting my body in the right place to be able to perform.”
Vodafone is also working with Cardiff Metropolitan University on a research study to further investigate the impact of the menstrual cycle by using the data gathered from PLAYER.Connect.
The ambition, the company says, is to provide information that can help all female athletes of all levels better manage their performance and wellbeing in the future.
“We are committed to using our network to find innovative ways to support the growth of women’s rugby in the UK from the grassroots up,” says Vodafone’s UK chief commercial officer, Max Taylor.
“We are only in the early stages of a long partnership with the WRU and we’re looking forward to working with the team in the coming years to deliver on our ambitious plans.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Fertility
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






